Table 3A.
Distribution of AR Expression in the Different Primary Tumor Subtypes
| Primary Tumor Subtypes (N. = 154) |
|||||
|---|---|---|---|---|---|
| LA* |
LB# |
LB-HER2+** |
TN^ |
HER2+ (HR-)@ |
|
| N. (%) | N. (%) | N. (%) | N. (%) | N. (%) | |
| Primary tumor | |||||
| AR negative (<1%) | 3 (9.4) | 8 (14.5) | 7 (17.9) | 5 (50.0) | 5 (27.8) |
| AR positive (≥1%) | 29 (90.6) | 47 (85.5) | 32 (82.1) | 5 (50.0) | 13 (72.2) |
| AR negative (<10%) | 4 (12.5) | 8 (14.5) | 9 (23.1) | 6 (60.0) | 7 (38.9) |
| AR positive (≥10%) | 28 (87.5) | 47 (85.5) | 30 (76.9) | 4 (40.0) | 11 (61.1) |
*
LA, luminal A-like: ER+, PgR ≥20%, Ki67< 20%, HER2−;
#
LB, luminal B-like: ER+, PgR <20% or Ki67 ≥ 20%, HER2−;
**
LB-HER2+, luminal B-like HER2-positive: ER+, PgR <20% or Ki67 ≥ 20%, HER2+;
^
TN, triple-negative: ER−, PgR−, HER2−;
@
HER2+ (HR−), HER2-positive, hormone receptor-negative: ER−, PgR−, HER2+.